RecruitingPhase 2NCT06590896
Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
A Phase 2, Multicenter Open-Label Extension Study to Evaluate the Long-term Safety of Cenobamate in Japanese Subjects With Partial Onset Seizures
Sponsor
Ono Pharmaceutical Co. Ltd
Enrollment
100 participants
Start Date
Nov 4, 2022
Study Type
INTERVENTIONAL
Conditions
Summary
To evaluate the long-term safety and tolerability of cenobamate in Japanese epilepsy patients with partial seizures
Eligibility
Inclusion Criteria1
- Subjects completed Study YKP3089C035 by SK Life Science.
Exclusion Criteria2
- Subjects that have previously discontinued for any reason from the Core study (YKP3089C035).
- Any significant changes to the medical history of the subject that in the opinion of the investigator, could affect the safety of the subject.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGCenobamate
Cenobamate will be orally administered once daily.
Locations(29)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06590896
Related Trials
High-resolution Multi-parametric Magnetic Resonance Imaging for Focal Epilepsy
NCT065507261 location
A Clinical Study on the Efficacy and Safety of Zonisamide as a First Add-On Treatment in Epileptic Seizures
NCT069670121 location
Treating Postictal Symptoms Using Ibuprofen and Nifedipine
NCT039494782 locations